{
  "title": "AstraZeneca’s Soriot on cures for pharma ills",
  "link": "http://www.breakingviews.com",
  "description": "The $208 bln drugmaker’s CEO is celebrating 10 years at the helm. In this edition of the Exchange podcast, he explains why after quadrupling the company’s share price, there is more to do. He also delves into Chinese competition and the consequences of caps on U.S. drug prices.\nLearn more about your ad choices. Visit megaphone.fm/adchoices",
  "pubDate": "Tue, 30 Aug 2022 10:19:49 -0000",
  "itunes:episodeType": "full",
  "itunes:author": "Reuters",
  "itunes:subtitle": "The $208 bln drugmaker’s CEO is celebrating 10 years at the helm. In this edition of the Exchange podcast, he explains why after quadrupling the company’s share price, there is more to do. He also delves into Chinese competition and the consequences of caps on U.S. drug prices.",
  "itunes:summary": "The $208 bln drugmaker’s CEO is celebrating 10 years at the helm. In this edition of the Exchange podcast, he explains why after quadrupling the company’s share price, there is more to do. He also delves into Chinese competition and the consequences of caps on U.S. drug prices.\nLearn more about your ad choices. Visit megaphone.fm/adchoices",
  "content:encoded": "<p>The $208 bln drugmaker’s CEO is celebrating 10 years at the helm. In this edition of the Exchange podcast, he explains why after quadrupling the company’s share price, there is more to do. He also delves into Chinese competition and the consequences of caps on U.S. drug prices.</p><p> </p><p>Learn more about your ad choices. Visit <a href=\"https://megaphone.fm/adchoices\">megaphone.fm/adchoices</a></p>",
  "itunes:duration": 3057,
  "guid": "6a46febe-284d-11ed-a9ff-e7742c45a94b",
  "enclosure": ""
}